Nephros Inc (NEPH) — SEC Filings
Nephros Inc (NEPH) — 23 SEC filings. Latest: 8-K (Nov 26, 2025). Includes 13 8-K, 6 10-Q, 2 DEF 14A.
Overview
Nephros Inc (NEPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: NEPHROS INC reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $1.132 million, a substantial improvement from a net loss of $0.275 million in the same period of 2024. Total net revenues surged by 36.6% to $14.060 million for the nine m
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 19 neutral, 1 mixed. The dominant filing sentiment for Nephros Inc is neutral.
Filing Type Overview
Nephros Inc (NEPH) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of NEPH's 21 recent filings, 0 were flagged as high-risk, 7 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $14.060M |
| Net Income | $1.132M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $5.171M |
| Operating Margin | 8.0% |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- NEPH:FirstPeoMember
- NEPH:SecondPeoMember
- Dr. Michael J. Z. Brown
Industry Context
NEPHROS INC operates in the medical device sector, specifically focusing on innovative technologies for kidney disease. The industry is characterized by high R&D investment, stringent regulatory requirements (FDA approval), and a competitive landscape with both established players and emerging companies. Trends include the development of less invasive treatments and improved patient monitoring solutions.
Top Tags
10-Q (4) · financials (4) · 8-k (3) · medical-devices (3) · financial-reporting (3) · Medical Devices (2) · Revenue Growth (2) · financial-results (2) · Quarterly Earnings (2) · executive-compensation (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $1.132M | For nine months ended Sept 30, 2025, a swing from a $0.275M loss in 2024. |
| Total Net Revenues | $14.060M | For nine months ended Sept 30, 2025, up 36.6% from $10.292M in 2024. |
| Net Cash from Operations | $1.415M | For nine months ended Sept 30, 2025, reversing a $1.796M outflow in 2024. |
| Customer A Revenue Concentration | 23% | Percentage of total revenues from Customer A for nine months ended Sept 30, 2025. |
| Top 3 Accounts Receivable Concentration | 36% | Percentage of accounts receivable from Customers C, A, and E as of Sept 30, 2025. |
| Accumulated Deficit | $143.2M | As of September 30, 2025, indicating historical losses despite recent profitability. |
| Cash and Cash Equivalents | $5.171M | As of September 30, 2025, up from $3.760M at December 31, 2024. |
| Product Revenues (Q3) | $4.596M | For the three months ended Sept 30, 2025, up from $3.472M in 2024. |
| Q2 2025 Product Revenue | $2.8M | Up 33.3% from $2.1M in Q2 2024 |
| Q2 2025 Total Revenue | $3.0M | Up 30.4% from $2.3M in Q2 2024 |
| H1 2025 Product Revenue | $5.5M | Up 34.1% from $4.1M in H1 2024 |
| H1 2025 Total Revenue | $5.9M | Up 31.1% from $4.5M in H1 2024 |
| Q2 Product Revenue Growth | 33.3% | Year-over-year increase for the quarter |
| Q2 Total Revenue Growth | 30.4% | Year-over-year increase for the quarter |
| Period End Date | 20250331 | Reporting period for the 10-Q filing. |
Frequently Asked Questions
What are the latest SEC filings for Nephros Inc (NEPH)?
Nephros Inc has 23 recent SEC filings from Mar 2024 to Nov 2025, including 13 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NEPH filings?
Across 23 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 19 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Nephros Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nephros Inc (NEPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nephros Inc?
Key financial highlights from Nephros Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NEPH?
The investment thesis for NEPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nephros Inc?
Key executives identified across Nephros Inc's filings include NEPH:FirstPeoMember, NEPH:SecondPeoMember, Dr. Michael J. Z. Brown.
What are the main risk factors for Nephros Inc stock?
Of NEPH's 21 assessed filings, 0 were flagged high-risk, 7 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Nephros Inc?
Forward guidance and predictions for Nephros Inc are extracted from SEC filings as they are enriched.